Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?

INTRODUCTION

Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature  osteocytes. There is no causative evidence information on the role of sclerostin in the pathogenesis of type 2 diabetes mellitus (T2DM) in humans.

AIM

This study aimed to investigate the relationship between serum sclerostin levels and oxidative status and biochemical parameters in T2DM patients and healthy people.

MATERIALS AND METHODS

This cross-sectional study, conducted in a clinical trial center, included 45 subjects with T2DM and 45 subjects as controls.

RESULTS

Serum sclerostin, total oxidative status (TOS), albumin, and ferritin levels were significantly higher in T2DM patients than in the control group (p<0.05). Total antioxidant status (TAS) was significantly higher in the control group (p<0.05). There was a weak positive correlation between sclerostin and TOS (r=0.23, p=0.03) and a weak negative correlation between sclerostin and TAS (r=-0.28, p=0.03).

CONCLUSIONS

We have demonstrated that serum sclerostin levels increase in patients with T2DM and that the increased sclerostin levels are associated with oxidative stress.